Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Sulfatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 21 Mar 2016 Results were published in a Chi-Med media release.
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
- 30 Oct 2015 Data will be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, according to a Hutchison MediPharma media release.